BioCentury
ARTICLE | Company News

UCB gains after boosting guidance

October 29, 2015 2:41 AM UTC

UCB Group (Euronext:UCB) gained EUR 4.29 to EUR 75.81 on Wednesday after reporting 3Q15 earnings and raising its guidance for 2015. The company raised its revenue guidance to EUR 3.75 billion ($4.14 billion) from a range of EUR 3.65-EUR 3.75 billion ($4.03-$4.14 billion), and raised core EPS guidance to EUR 2-EUR 2.10 from EUR 1.90-EUR 2.05.

The company's total sales for the first nine months of 2015 were EUR 2.9 billion, up 12% from the same period in 2014 at constant exchange rates. The company attributed most of its growth to increased sales of Cimzia certolizumab pegol, Vimpat lacosamide and Neupro rotigotine. ...